Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer – An update

REFERENCES

• Neglia JP, Friedman DL, Yasui Y et al. Second malignant neoplasms in five-year survivors of childhood cancer: child-hood cancer survivor study. J Natl Cancer Inst 2001;93:618 — 629.
   Google Scholar
• Kantarjian HM, Keating MJ, Walters RS et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic and prognostic features. J Clin Oncol 1986;4:1748–1757.
   Google Scholar
• Pedersen-Bjergaard J, Andersen MK, Christiansen DH et al. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002;99:1909–1912.
   Google Scholar
• Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochem Biophys Acta 1998;1400:233–255.
   Google Scholar
• Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000;95:3273–3279.
   Google Scholar
• Leone G, Voso MT, Sica S et al. Therapy-related leukemias: susceptibility, prevention and treatment. Leuk Lymphoma 2001;41:255–276.
   Google Scholar
• Felix CA. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 2001;36:525–535.
   Google Scholar
• Latagliata R, Petti MC, Fenu S et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002;99:822–824.
   Google Scholar
• Meadows AT, Baum E, Fossati-Bellani et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol 1985;3:532–538.
   Google Scholar
• Bhatia S, Ramsey NKC, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996;87:3633–3639.
   Google Scholar
• Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer 2002;2:124–132.
   Google Scholar
• Pui C-H, Ribeiro RC, Hancock ML et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoid leukemia. N Eng Med J 1991;325:1682–1687.
   Google Scholar
• Neglia JP, Meadows AT, Robison LL et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Eng J Med 1991;325:1330–1336.
   Google Scholar
• Kreissman SG, Gelber RD, Cohen HJ et al. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer 1992;70:2208–2213.
   Google Scholar
• Dalton VMK, Gelber RD, Li F et al. Second malignancies in patients treated for childhood acute lymphoblastic leukemia. J Clin Oncol 1998;16:2848–2953.
   Google Scholar
• Loning L, Zimmermann M, Reiter A et al. Secondary neoplasms subsequent to Berlin- Frankfurt- Munster ther-apy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000;95:2770–2775.
   Google Scholar
• Bhatia S, Sather HN, Pabustan OB et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 2002;99:4257–4264.
   Google Scholar
• Wolden SL, Lamborn KR, Cleary SF et al. Second cancers following pediatric Hodgkin's disease. J Clin Oncol 1998;16:536–544.
   Google Scholar
• Milligan DW, de Elvira CR, Kolb H-J et al. Secondary leukaemia and myelodysplasia after autografting for lympho-ma: results from the EBMT. Br J Haematol 1999;106:1020–1026.
   Google Scholar
• Andre M, Henry-Amar M, Blaise D et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998;92:1933–1940.
   Google Scholar
• Nichols KE, Levitz S, Shannon KE et al. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol 1999;17:1259.
   Google Scholar
• Mott MG, Boyse J, Hewitt M et al. Do mutations at the glycophorin A locus in patients treated for Hodgkin's disease predict secondary leukaemia? Lancet 1994;343:828–829.
   Google Scholar
• Leung W, Sandlund JT, Hudson MM et al. Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer 2001;92:1959–1966.
   Google Scholar
• Krishnan A, Bhatia S, Slovak ML et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000;95:1588–1593.
   Google Scholar
• Metayer C, Curtis RE, Vose J et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplanta-tion for lymphoma: a multicenter case-control study. Blood 2003;101:2015–2023.
   Google Scholar
• Lillington DM, Micallef INM, Carpenter E et al. Genetic susceptibility to Hodgkin's disease and secondary neoplasias: FISH analysis reveals patients at high risk of developing secondary neoplasia. Ann Oncol 2002;13\(Suppl. 1):40–43.
   Google Scholar
• Micallef INM, Lillington DM, Apostolidis J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hemato-poietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000;18:947–955.
   Google Scholar
• Pratt CB, Meyer WH, Luo X et al. Second malignant neoplasms occurring in survivors of osteosarcoma. Cancer 1997;80:960–965.
   Google Scholar
• Bhatia S, Krailo M, Schwartz et al. Therapy-related myelodysplasia [t-MDS/ t-AML] following treatment of children with osteosarcoma. Am Soc Clin Oncol 2001;20:369a (abstract 1473).
   Google Scholar
• Aung L, Gorlick RG, Shi W et al. Second malignant neoplasms in long-term survivors of osteosarcoma. Memorial Sloan-Kettering Cancer Center experience. Cancer 2002;95:1728–1734.
   Google Scholar
• Miser J, Krailo M, Smith M et al. Secondary leukemia (SL) or myelodysplastic syndrome (MDS) following therapy for Ewing's sarcoma (ES). Proc Am Soc Clin Oncol 1997;16:1863 (abstract).
   Google Scholar
• Rodriguez-Galindo C, Poquette CA, Marina NM et al. Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified che-motherapy for the Ewing sarcoma family of tumors. J Pediatr Hematol/Oncol 2000;22:321–329.
   Google Scholar
• Pui C-H, Hancock ML, Raimondi SC et al. Myeloid neoplasia in children treated for solid tumors. Lancet 1990;336:417–421.
   Google Scholar
• Breslow NE, Takashima JR, Whitton JA et al. Second malignant neoplasms following treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1995;13:1851–1859.
   Google Scholar
• Shearer P, Kapoor G, Beckwith JB et al. Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors: a report from the National Wilms Tumor Study Group. J Pediatr Hematol/Oncol 2001;23:109–111.
   Google Scholar
• Miwa H, Beran M, Sanders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992;6: 405–409.
   Google Scholar
• Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy related acute myeloid leukemia and myelodysplastic syndrome. Blood 1985;65:1364–1372.
   Google Scholar
• Kouides PA, Bennett JM. Morphology and classification of the myelodysplastic syndromes and their pathologic variants. Semin Hematol 1996;33:95–110.
   Google Scholar
• Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620–625.
   Google Scholar
• Bennett JM, Catovsky D, Daniel MT et al. Criteria for the diagnosis of acute leukemia of megakaryocytic lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:460–462.
   Google Scholar
• Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Hae-matol 1982;51:189–199.
   Google Scholar
• Barnard DR, Lange BJ, Alonzo TA et al. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood 2002;100:427–434.
   Google Scholar
• Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neo-plasms. Blood 2002;100:2292–2302.
   Google Scholar
• Rege KP, Janes SL, Saso R et al. Secondary leukaemia characterised by monosomy 7 occurring post-autologous stem cell transplantation for AML. Bone Marrow Transplant 1998;21:853–855.
   Google Scholar
• Kebelmann-Betzing C. Secondary acute myeloid leukemia after treatment of acute monoblastic leukemia. N Eng J Med 2000;343:1897–1898.
   Google Scholar
• Kondoh K, Nakata Y, Furuta T et al. A pediatric case of secondary leukemia associated with t(16;21)(q24;q22) ex-hibiting the chimeric AML1-MTG16 gene. Leuk Lymphoma 2002;43:415–420.
   Google Scholar
• Amigo ML, del Canizo MC, Rois A et al. Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS. Bone Marrow Transplant 1999;23:997–1002.
   Google Scholar
• Laurenti L, d'Onofrio G, Sica S et al. Secondary myelodys-plastic syndromes following peripheral blood stem cell transplantation: morphological, cytogenetic and clonality evaluation and the limitation of FAB criteria. Bone Marrow Transplant 2000;26:241–242.
   Google Scholar
• Chu JY, Batanian JR, Gale GB et al. Spontaneous resolution of myelodysplastic cytogenetic abnormality developed during the treatment of leukemia. J Pediatr Hematol/Oncol 1998;20:88–90.
   Google Scholar
• Seiter K, Feldman EJ, Sreekantaiah C et al. Secondary acute myelogenous leukemia and myelodysplasia without abnorm-alities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy. Leu-kemia 2001;15:963–970.
   Google Scholar
• Andersen MK, Pedersen-Bjergaard J. Therapy-related MDS and AML in acute promyelocytic leukemia. Blood 2002;100:1928–1929.
   Google Scholar
• Rowley JD. Rearrangements involving chromosome band 11q23 in acute leukemia. Semin Cancer Biol 1993;4:377–385.
   Google Scholar
• Rowley JD, Reshmi S, Sobulo 0 et al. All patients with the t[l 1;16] [q23;p13.3] that involves MLL and CBP have treat-ment-related hematologic disorders. Blood 1997;90:535–541.
   Google Scholar
• Atlas M, Head D, Behm F et al. Cloning and sequence analysis of four t[9;11] therapy-related leukemia breakpoints. Leukemia 199812:1895-1902.
   Google Scholar
• Langer T, Metzler M, Reinhardt D et al. Analysis of t[9;11] chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides. Genes Chromosomes Cancer 2003;36:393–401.
   Google Scholar
• Quesnel B, Kantarjian H, Pedersen-Bjergaard J et al. Therapy-related acute myeloid leukemia with t(8;21), inv 16 and t(8;16). A report on 25 cases and review of the literature. J Chin Oncol 1993;11: 2370–2379.
   Google Scholar
• Pedersen-Bjergaard J, Brondum-Nielsen K, Karle H et al. Chemotherapy-related and late occurring Philadelphia chro-mosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase II inhibitors? Leukemia 1997;11:1571–1574.
   Google Scholar
• Forestier E, Heim S, Blennow E et al. Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001. Br J Haematol 2003;121:566–577.
   Google Scholar
• Harada H, Harada Y, Tanaka H et al. Implications of somatic mutations in the A1v1L1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 2003;101:673–680.
   Google Scholar
• Mauritzson N, Albin M, Rylander Let al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002;16:2366–2378.
   Google Scholar
• Nabhan C, Peterson LA, Kent SA et al. Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin lymphoma. Leuk Lymphoma 2002;43:2145–2149.
   Google Scholar
• Schoch C, Schnittger S, Kern W et al. Acute myeloid leukemia with recurring chromosomal abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia. Haematologica 2003;88:351–352.
   Google Scholar
• Preisler HD. Evolution of secondary hematologic disorders: pre-MDS MDS- sAML. Cancer Treat Res 2001;108: 185–230.
   Google Scholar
• Davies SM. Therapy-related leukemia associated with alkylating agents. Med Pediatr Oncol 2001;36:536–540.
   Google Scholar
• Le Deley M-C, Leblanc T, Shamsaldin A et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracy-clines: a case-control study by the Societe Francaise d'Oncologie Pediatrique. J Chin Oncol 2003;21:1074–1081.
   Google Scholar
• Smith MA, Rubinstein L, Anderson JR et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Chin Oncol 1999;17:569–577.
   Google Scholar
• Karp JE, Smith MA. Modifying risks of secondary leukemias: is drug scheduling important. J Natl Cancer Inst 1996;88:1787–1789.
   Google Scholar
• Haupt R, Fears TR, Heise A et al. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langer-hans' cell histiocytosis in Italian and Austrian-German population. Int J Cancer 1997;71:9–13.
   Google Scholar
• Deininger MWN, Bose S, Gora-Tybor J et al. Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation. Cancer Res 1998;58:421–425.
   Google Scholar
• Weiss B, Vora A, Huberty J et al. Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylgua-nidine therapy for relapsed neuroblastoma. J Pediatr Hematol/Oncol 2003;25:543–547.
   Google Scholar
• Smith SM, Le Beau MM, Huo D et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodys-plasia and myeloid leukemia: the University of Chicago series. Blood 2003;102:43–52.
   Google Scholar
• Fassas AB, Tricot G. Myelodysplastic syndromes complicat-ing hematopoietic stem cell transplantation. Cancer Treat Res 2001;108:169–184.
   Google Scholar
• Forrest DL, Nevill TJ, Naiman SC et al. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis. Bone Marrow Transplant 2003;32:915–923.
   Google Scholar
• Lambertenghi-Deliliers G, Annaloro C, Pozzoli E et al. Cytogenetic and myelodysplastic alteration after autologous hematopoietic stem cell transplantation. Leukemia Res 1999;23:291–297.
   Google Scholar
• Sevilla J, Rodriguez A, Hernandez-Maraver D et al. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation. Ann Hematol 2002;81:11–15.
   Google Scholar
• Relling MV, Boyett JM, Blanco JG et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003;101:3862–3867.
   Google Scholar
• Clark JJ, Smith FO, Arceci RJ. Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies. Curr Opin Hematol 2003;10:31–39.
   Google Scholar
• Marcaigh AS, Shannon KM. Role of NF1 gene in leukemogenesis and myeloid growth control. J Pediatr Hematol/Oncol 1997;19:551–554.
   Google Scholar
• Perentesis JP. Genetic predisposition and treatment-related leukemia. Med Pediatr Oncol 2001;36:541–548.
   Google Scholar
• Pagana L, Pulsoni A, Tosti ME et al. Clinical and biological features of acute myeloid leukemia occurring as second malignancy: GIMEMA archive of adult acute leukemia. Br J Haematol 2001;112:109–117.
   Google Scholar
• Chen H, Sandler DP, Taylor JA et al. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 1996;347:295–296.
   Google Scholar
• Woo MH, Shuster JJ, Chen C et al. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia 2000;14:232–237.
   Google Scholar
• Allan JM, Wild CP, Rollison S et al. Polymorphism in glutathione 5-transferase P1 associated with susceptibility to chemotherapy-induced leukemia. PNAS 2001;98:11592–11597.
   Google Scholar
• Larson RA, Wang Y, Banerjee et al. Prevalence of the inactivating 609C -T polymorphism in the NAD[P]H:qui-none oxidoreductase (NQ01) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999;94:803–807.
   Google Scholar
• Relling MV, Yanishevski Y, Nemec J et al. Etoposide and antimetabolite pharmacology in patients who develop sec-ondary acute myeloid leukemia. Leukemia 1998;12:346–352.
   Google Scholar
• Seedhouse C, Bainton R, Lewis M et al. The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood 2002;100:3761–3766.
   Google Scholar
• Stone RM. Treatment of acute myeloid leukemia: state-of-the-art and future directions. Semin Hematol 2002;39:4–10.
   Google Scholar
• Head DR Revised classification of acute myeloid leukemia. Leukemia 1996;10:1826–1831.
   Google Scholar
• Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318–1327.
   Google Scholar
• Meltzer PS. MDM2 and p53: a question of balance. J Natl Cancer Inst 1994;84:1265–1266.
   Google Scholar
• Felix CA, Hosler MR, Provisor D et al. The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood 1996;87:4376–4381.
   Google Scholar
• Ben-Yehuda D, Krichevsky S, Caspi et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996;88:4296–4303.
   Google Scholar
• Gustafsson B, Christenson B, Gustafsson B et al. Cellular expression of MDM2 and p53 in childhood leukemias with poor prognosis. Med Pediatr Oncol 2000;34:117–124.
   Google Scholar
• Nagai M, Fujita M, Ikeda T et al. Alterations of p53 and Rb genes in a novel human GM-CSF-dependent myeloid cell line (01-IN-GM) established from therapy-related leukaemia. Br J Haematol 1997;98:392–398.
   Google Scholar
• Qian Z, Fernald AA, Godley LA et al. Expression profiling of CD34 + hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. PNAS 2002;99:14925–14930.
   Google Scholar
• Boyse J, Hewitt M, Mott MG. Glycophorin A mutations and risk of secondary leukaemia in patients treated for childhood acute lymphoblastic leukaemia. Br J Haematol 1996;93:117–124.
   Google Scholar
• Sandler ES, Friedman DJ, Mustafa MM et al. Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia. Cancer 1997;79:1049–1054.
   Google Scholar
• Visani G, Pagano L, Pulsoni A et al. Chemotherapy of secondary leukemias. Leuk Lymphoma 2000;37:543–549.
   Google Scholar
• Beaumont M, Sanz M, Carli PM et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003;21:2123–2137.
   Google Scholar
• Pollicardo N, O'Brien S, Estey EH et al. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution. Leukemia 1996;10:27–31.
   Google Scholar
• Rege K, Swansbury GJ, Atra AA et al. Disease features in acute myeloid leukemia with t[1;21] [q22; (122]. Influence of age, secondary karyotype abnormalities, CD19 status and extramedullary leukemia on survival. L,euk Lymphoma 2000;40: 67–77.
   Google Scholar
• Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic. Genes Chromosomes Cancer 2002;33:331–345.
   Google Scholar
• Leahey AM, Friedman DL, Bunin NJ. Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. Bone Marrow Transplant 1999;23:21–25.
   Google Scholar
• Hale GA, Heslop HE, Bowman LC et al. Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant 1999;24:735–739.
   Google Scholar
• Estey EH. Prognosis and therapy of secondary myelodys-plastic syndromes. Haematologica 1998;83:543–549.
   Google Scholar
• Wattel E. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P-glycoprotein: results of a randomized study. Br J Haematol 1998;102:1015–1024.
   Google Scholar
• Hermida G, Manjon R, Rodriguez-Salazar I, Richard C. Treatment of a secondary myelodysplastic syndrome after allogenic bone marrow transplantation using Mylotarg. Haematology 2002;87: [04]ECR14.
   Google Scholar
• Auletta JJ, Shurin S. Improved hematopoiesis using amifos-tine in secondary myelodysplasia. J Pediatr Hematol/Oncol 1999;21:531–534.
   Google Scholar
• List AF, Heaton R, Glinsmann-Gibson B et al. Amifostine stimulates formation of multipotent progenitors and gener-ates macroscopic colonies in normal and myelodysplastic bone marrow. Proc Am Soc Clin Oncol 1996;15:449.
   Google Scholar
• Steinmetz FIT, Schulz A, Staib P et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside and filgrastim (Ida-FLAG) for treatment of refractory, relapsed and secondary AML. Ann Hematol 1999;78:418–425.
   Google Scholar
• He X-Y, Elson P, Pohlman B et al. Timed sequential chemotherapy with concomitant granulocyte colony-stimu-lating factor for high-risk acute myelogenous leukemia: a single arm clinical trial. BMC Cancer 2002;2:12–18.
   Google Scholar
• Kindler T, Breitenbuecher F, Marx A et al. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. Blood 2003;101:2960–2962.
   Google Scholar
• Tsutsumi C, Ueda M, Miyazaki Y et al. DNA microarray analysis of dysplastic morphology associated with acute myeloid leukemia. Exp Hematol 2004;32:828–835.
   Google Scholar
• Perentesis JP, Sievers EL. Targeted therapies for high-risk acute myeloid leukemia. Hematol/Oncol Clin North Am 2001;15:677–701.
   Google Scholar
• Fiedler W, Mesters R, Tinnefeld H et al. A phase II clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003;102:2763–2767.
   Google Scholar
• Mantadakis E, Kalmanti M. New antileukemic agents. Pediatr Hematol Oncol 2003;20:173–185.
   Google Scholar